• Markus Mach, Victoria Watzal, Carina Cuhaj, Waseem Hasan, Thomas Poschner, Philipp Szalkiewicz, Andreas Strouhal, Christopher Adlbrecht, Georg Delle-Karth, Martin Grabenwöger, and Bernhard Winkler.
• Department of Cardiac Surgery, Medical University of Vienna, Vienna, Austria.
• Eur. J. Clin. Invest. 2021 Sep 1; 51 (9): e13589.

BackgroundWe compared the outcomes and adverse events of TAVI patients based on the discharge and long-term antiplatelet or anticoagulant treatment regimens (single antiplatelet [SAPT] vs. dual antiplatelet [DAPT] vs. anticoagulation [OAC] vs. no treatment [NT]).MethodsThe outcome of 532 consecutive patients treated with TAVI was evaluated. As the main study endpoint, the 1-year all-cause mortality was chosen to compare the different discharge treatment regimens and the 3-year all-cause mortality to compare the different long-term treatment regimens. The secondary endpoints were adverse events as defined by the Valve Academic Research Consortium-II.ResultsOne-year survival after TAVI was highest amongst patients treated with DAPT compared to SAPT (P < .001) and OAC (P = .003), and patients under OAC demonstrated improved 1-year survival over patients treated with SAPT (P = .006). Furthermore, there was a strong trend towards improved 3-year survival for patients in the OAC cohort treated with non-vitamin K antagonists compared to vitamin K antagonists (N-VKAs vs. VKA; log-rank P = .056).ConclusionThe lower all-cause mortality for DAPT within the first year and N-VKAs over VKA within the first 3 years warrant considerable attention in further recommendations of antithrombotic and anticoagulation regimens after TAVI.© 2021 Stichting European Society for Clinical Investigation Journal Foundation. Published by John Wiley & Sons Ltd.

4 keywords...

hide…